Podcasts about medical science

In part two of this conversation, host Emma Sellers, MS, continues her discussion with Lucy Kibe, DrPH, MS, MHS, PA-C, co-founder of AmKeny, a nonprofit organization connecting U.S. physician associates and clinicians with Kenyan clinical officers to support healthcare, education, and community initiatives in Kenya. Joining the conversation are Laye Akinloye, PA-C, Emeritus; Alabi Akinloye, PA; Miriam Ha, PA; and pre-PA students Gaelen Waar and Ajana Williams, who reflect on their experiences participating in AmKeny's medical outreach work in Kitale, Kenya. The group discusses the global role of physician associates and similar professions such as Kenya's clinical officers, highlighting the impact of collaborative, community-centered care. Miriam and the clinicians share lessons learned through service, listening, and cultural exchange, while Gaelen and Ajana describe transformative moments working alongside healthcare teams, including helping connect dozens of patients to free cataract surgeries through an eye clinic initiative. The episode also explores the importance of teamwork, cultural communication, and sustainable support efforts, as Lucy shares AmKeny's plans for future outreach trips and encourages support through local supply purchases and donations. Along the way, the guests reflect on the relationships built through the experience, as well as the opportunity to explore Kenya's culture, communities, and landscapes. This episode is sponsored by Lincoln Memorial University School of Medical Sciences. For more information about the doctor of medical science program, visit https://www.lmunet.edu/school-of-medical-sciences/dms/. For more information on the medical education major curriculum, visit https://www.lmunet.edu/school-of-medical-sciences/dms/medical-education-major-curriculum. The PA Path Podcast is produced by Association Briefings.

Carlos Juan Finlay was a Cuban doctor who did a lot of work to understand the spread of Yellow Fever. But Walter Reed got most of the credit. Research: American Experience. “Carlos Finlay (1833-1915).” From The Great Fever. PBS. https://www.pbs.org/wgbh/americanexperience/features/fever-carlos-finlay/ Berenbrok, Dorothy E., "Latin Heritage Month. Carlos Juan Finlay: Outrageous, Courageous and Correct" (2015). Posters: Jefferson History. 3. https://jdc.jefferson.edu/jeffhistoryposters/3 "Carlos Juan Finlay." Encyclopedia of World Biography Online, Gale, 1998. Gale In Context: Opposing Viewpoints, link.gale.com/apps/doc/K1631002194/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=bfeecc25. Accessed 29 Apr. 2026. Chaves-Carballo, Enrique. “Carlos J. Finlay: The mosquito man.” Hektoen International. 11/2/2020. https://hekint.org/2020/11/02/carlos-j-finlay-the-mosquito-man/ Corbitt, Duvon C. “Carlos J. Finlay, Cuban Physician.” The Hispanic American Historical Review, Vol. 45, No. 3 (Aug., 1965). Via JSTOR. https://www.jstor.org/stable/2511751 Del Regato, Juan A. “Carlos Juan Finlay (1833-1915).” Journal of Public Health Policy , 2001, Vol. 22, No. 1 (2001). Via JSTOR. https://www.jstor.org/stable/3343556 Faerstein, Eduardoa; Winkelstein, Warren Jrb. Carlos Juan Finlay: Rejected, Respected, and Right. Epidemiology 21(1):p 158, January 2010. | DOI: 10.1097/EDE.0b013e3181c308e0 Ferreira Moreno, Víctor Guillermo. “Evocation to the Dr. Carlos J. Finlay Barres on the centennial of his death.” Colombia medica (Cali, Colombia) vol. 47,1 63-6. 30 Mar. 2016 Finlay, Carlos J. “The Mosquito Hypothetically Considered as the Agent of Transmission of Yellow Fever.” Read before the Royal Academy of Medical, Physical and Natural Sciences Session of August 14th, 1881. https://archive.org/details/b33448541/page/590/mode/1up Finlay, Carlos Juan. “Trabajos selectos del Dr. Carlos J. Finlay. Selected papers of Dr. Carlos J. Finlay.” Habana. 1912. https://archive.org/details/trabajosselectos00finl Finlay, Charles. “Inoculations for Yellow Fever by Means of Contaminated Mosquitoes.” Published in The American Journal of the Medical Sciences, n.s. 102: 264-268, 1891. https://archive.org/details/b33445242/page/n4/mode/1up Finlay, Charles. “Yellow Fever: Its ‘Transmission by Means of the Culex Mosquito.” Published in The American Journal of the Medical Sciences, n.s. 92: 395-409, 1886. https://archive.org/details/b33435698/page/613/mode/1up Palmer, Steven. “A Cuban Scientist Between Empires: Peripheral Vision on Race and Tropical Medicine.” Canadian Journal of Latin American and Caribbean Studies / Revue canadienne desétudes latino-américaines et caraïbes, Vol. 35, No. 69, Special Issue: Landscapes of LatinAmerican Health, 1870-1970. Via JSTOR. https://www.jstor.org/stable/41800498 Spears, Ellen Griffith and Rosa López-Oceguera. “Carlos Juan Finlay, William Gorgas, and Walter Reed and the U.S. Army Yellow Fever Controversy: Competing Historical Memories.” Alabama Review The University of Alabama Press. Volume 74, Number 1, January 2021. https://doi.org/10.1353/ala.2021.0011 Stepan, Nancy. “The Interplay between Socio-Economic Factors and Medical Science: Yellow Fever Research, Cuba and the United States.” Social Studies of Science , Nov., 1978, Vol. 8, No. 4 (Nov., 1978). Via JSTOR. http://www.jstor.com/stable/284817 Thomas Jefferson University. “10 Notable Jefferson Alumni of the Past.” https://library.jefferson.edu/archives/exhibits/notable_alumni/juan_carlos_finlay.cfm Tone, John Lawrence. (2002) “How the mosquito (man) liberated Cuba.” History and Technology, 18:4, 277-308, DOI: 10.1080/07341512.2002.11417735 “Carlos J. Finlay.” 5/16/2023. https://www.unesco.org/en/prizes/carlos-j-finlay/about Woodall, Jack. "Yellow Fever." Infectious Diseases: In Context, edited by Brenda Wilmoth Lerner and K. Lee Lerner, vol. 2, Gale, 2008, pp. 925-931. In Context Series. Gale In Context: Opposing Viewpoints, link.gale.com/apps/doc/CX3045200265/GPS?u=mlin_n_melpub&sid=bookmark-GPS&xid=bf646a26. Accessed 29 Apr. 2026. See omnystudio.com/listener for privacy information.

Description: "When joint pain is present, the diagnosis of psoriatic arthritis needs to be made as soon as possible, ideally within six months to limit joint inflammation" Dr. Vinod Chandran mentions as he discusses efforts to identify a diagnostic test for those at risk of developing psoriatic arthritis.          Join host Jeff Brown as he speaks with leading rheumatologist and clinician scientist Dr. Vinod Chandran, Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto to learn more about the progress and promising results towards developing a psoriatic arthritis diagnostic test through multi-omic assays and identifying the distinct differences between psoriasis and psoriatic arthritis.  This episode provides an update on the progress to date of the NPF PsA Diagnostic Test grant initiative which has shown promising results with a potential test entering prospective study in multiple sites soon.   Thank you to Johnson and Johnson for their support of this program activity. Timestamps: (0:00)          Intro to Psoriasis Uncovered & guest welcome rheumatologist Dr. Vinod Chandran.    (0:52)          It is challenging to diagnose psoriatic arthritis with many factors leading to a delay in diagnosis. (4:56)          The start of Dr. Chandran's involvement with the PsA Diagnostic Test Grant project.   (7:55)          The different types of omics and the definition of multi-omic. (9:57)          How the multi-omic approach is used to find biomarkers relative to a specific disease pattern. (11:08)        Development of a predictive or prevention-based test using gene expression.      (13:46)        First year results identify 200 markers across different omic approaches that distinguish psoriatic arthritis from psoriasis.    (14:58)        The significance of MRNA vs mIcroRNA's use in development of a diagnostic test and how critical that is to dissemination of a                     potential test. (17:08)        Identifying the skin-joint axis in relation to different types of arthritis. (20:20)        Next steps to moving the diagnostic test research forward as a prospective study in multiple sites and the cost effectiveness of                  delivering the test.   (23:13)        If you have psoriasis, musculoskeletal, back, and joint pain think of psoriatic arthritis and be diagnosed early to maintain a good                 quality of life. Key Takeaways: ·       Given challenges associated with diagnosing psoriatic arthritis and the impact on quality of life, in 2019 NPF launched the PsA Diagnostic Test Grant project with the goal of developing an early stage test that would identify and diagnose those with psoriatic arthritis before debilitating  joint damage begins.   ·       Progress towards a PsA Diagnostic Test includes the study of multi-omic data sets where 200 distinct biomarkers have been identified leading to a greater understanding of the different pathways between psoriatic arthritis, psoriasis, and the skin joint axis.  ·       A potential diagnostic test is now moving towards the prospective study phase. Until the test is available and if joint pain is present and you have psoriasis, ask your health care provider if it could be psoriatic arthritis and treat appropriately.  Guest Bio: Vinod Chandran, MBBS, MD, DM, PhD is a rheumatologist, clinician scientist, and Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto where he is also a Professor of Medicine. His specialties include internal medicine, immunology, rheumatology, and genetic epidemiology. His research focus is on the development of biomarker-based strategies to improve early diagnosis and prognosis of psoriasis and psoriatic arthritis, identification of new treatment targets especially for those who do not respond to current therapies, and strategies to reduce the impact of disease. Dr. Chandran is a Co-Vice President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis or GRAPPA. He is an active collaborator in a multi-center research consortia such as the International Psoriasis and Arthritis Research Team and the Spondyloarthritis Research Consortium of Canada. Dr. Chandran is the recipient of research funding from the National Psoriasis Foundation for his work in identifying a "Multi-omic Diagnostic Test for PsA in Psoriasis Patients". Resources: "Understanding the NPF Psoriatic Arthritis Diagnostic Test Grant Outcomes" Advance Online. February 18, 2026.  "Managing Chronic Pain with Psoriatic Arthritis" Psoriasis Uncovered podcast episode with physiatrist Dr. Erin Maslowski, LB Herbert who lives with psoriatic disease, and moderator Susan McClelland-Tobert, a retired pediatric cardiologist who also lives with psoriatic disease. Glossary of terms: mRNA: Messenger RNA carries protein information or instructions from the DNA in a cell's nucleus to the cell's interior where the sequence is read and translated into corresponding amino acids for growing protein chains. Micro-RNA (miRNA):  Micro-RNA act as the regulator. They are short and bind to specific target mRNA's to degrade or inhibit production of protein. 

Una revisione dell’Università di Bologna pubblicata sulla rivista Medical Sciences ha analizzato 32 linee guida internazionali e ha ricostruito quarant'anni di evoluzione. Ne parliamo a Obiettivo Salute con il professor Claudio Borghi, Professore di Medicina Interna all'Università Alma Mater di Bologna, che ha partecipato allo studio

Rumble Video Link:https://rumble.com/v7931km-architects-of-inversion-hijacking-medical-science.htmlMy site:https://SemperFryLLC.comJoin Us and Make Dr. Glidden Your Doctorhttps://leavebigpharmabehind.com/?via=pgndhealth⁠Code: baalbusters for 25% OFF Annual MembershipThe 90 Essential Nutrients we need to function in the manner God intended have been removed, replaced, and the knowledge hidden and stolen from the soil, and from the food we eat.  Fortunately there is a whole-food source for the vital nutrients and minerals we are otherwise deprived of.Get you 90 Essential Nutrients with supplements designed by Dr. Monzo.Use Code BB5 here:https://www.azurestandard.com/shop/brand/azurewell/2326The Azure 90 Essentials are as follows: 1. Whole Food Multivitamin, 2. Alaskan Cod Liver Oil, 3. Fulvic-Humic Energy Blend, 4. IP6 Supreme. Use code BB5 for your discount.The Rothschilds backed the fraudster Pasteur promoting false scientific claims that lead to very deadly and incorrect beliefs in the cause, the mechanism, and the remedy for illnesses. This was done deliberately to implelent a genocidal Eugenics program hiding in plain sight, disguised as your modern healthcare.  The information I bring you is for educational purposes and out of sincere care for you, so that you may break the spell of false Scientism prevalent in the destructive therapies of allopathic medicine. There is an alternative and the healing begins with supplying yourself with vital nutrients.  The medical cult denies the healing powers of minerals, nutrients of food, replaces them with chemicals, and prescribes harmful drugs who's purpose isn't to cure the condition. They simply suppress the symptoms which leads to further degradation and poisoning of your body. Become a supporter of this podcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262/support.

The link between sleep and epilepsy is powerful, complex, and often overlooked. We know that sleep loss and disruptions can trigger seizures in epileptic patients. We also know that repeated seizures during sleep can fragment sleep and reduce the brain's ability to recover. In this episode, we sit down with Dr Shukla, a neurologist specializing in Epilepsy and Sleep, and discuss the intersection of sleep and epilepsy. We talk about the link between sleep disorders and epilepsy, how doctors diagnose sleep-related issues in epilepsy and why treating sleep problems can be an important part of seizure management. Dr. Garima Shukla is a Professor of Neurology, specializing in Epilepsy and Sleep Medicine; and faculty at the Center for Neuroscience studies at the Queen's University in Kingston, ON, Canada. Her prior appointment was as Professor of Neurology at the All India Institute of Medical Sciences, New Delhi, India. Her research focuses on clinical and neurophysiological aspects of the sleep-epilepsy-cognition interface and epilepsy co-morbidities as well as neurological sleep disorders, particularly phenotypes and course of Restless legs syndrome. Her team is currently investigating the role of wake and sleep high-density EEG source localization in predicting overall epilepsy outcomes (seizure control, cognition and mood). Authors: Golnar Taheri, Eve Racette Email: thinktwicepodcast@outlook.com Instagram: @thinktwice_podcast LinkedIN: Think Twice Podcast Patreon: https://www.patreon.com/ThinkTwicePodcast Disclaimer: Think Twice is a podcast for general information and entertainment purposes only. The content discussed in the episodes does not reflect the views of the podcast committee members or any institution they are affiliated with. The use of the information presented in this podcast is at the user's own risk and is not intended to replace professional healthcare services.

Prof Angus Dalgleish is a professor emeritus of oncology at St Georges-University of London and a visiting professor at the institute of Cancer Research in London, who is recognized worldwide for his contributions in cancer and HIV research. Dr. Dalgleish is the co-discoverer of identifying the CD4 receptor as a major cellular receptor for HIV. He has published approximately 500 papers in the peer-reviewed literature, and is a fellow of the Academy of Medical Sciences and the Royal College of Physicians. Early during the Covid pandemic, Dr. Dalgleish was a member of a selective group that as early as March 2020, just a few months after the first announcement of the pandemic coronavirus, claimed the Covid-19 virus originated from the Wuhan Institute of Virology. Gus has been an outspoken critic of government lockdowns, mask mandates and the Covid vaccines, notably the mRNA vaccines by Pfizer and Moderna.

In this episode of CURiE Conversations on the ACRO Podcast, Dr. Veronia Fahmy speaks with author Dr. Niema Razavian about his published article, “Results From the Practice Accreditation Resident Reviewer Program (PARRP) Pilot: Educating Radiation Oncology Residents About Practice Accreditation.”Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article on Cureus:https://www.cureus.com/articles/438644-results-from-the-practice-accreditation-resident-reviewer-program-parrp-pilot-educating-radiation-oncology-residents-about-practice-accreditation.

Democrats and Republicans are cleaning house this week: both Eric Swalwell and Tony Gonzales resigned from Congress following a wave of scandals. Dr. Drew is taking your calls and wants to know: Are they “innocent until proven guilty” or is the evidence so strong that they just needed to go? Global tensions continue to escalate as the Iran War continues. And in a rare move, President Trump deleted one of his Truth Social posts that many perceived as blasphemy – was this a smart move, or did he bend to the mob? Joining Dr. Drew to answer calls is ophthalmologist and surgeon Dr. Azadeh Khatibi, who fights for bodily autonomy and medical freedom in Sacramento. Dr. Azadeh Khatibi is a fellowship-trained and board-certified ophthalmologist, surgeon, physician-scientist, filmmaker, actress, teacher, and activist. She is currently working on a film about free speech in medicine. She hosts the show WITHIN with Dr. Azadeh Khatibi, MD, MS, MPH on YouTube, Spotify, Rumble and podcast platforms. She was a Regent's Scholar at UCLA, graduating Phi Beta Kappa with Highest Departmental Honors in Molecular, Cell, Developmental Biology. She studied at UCSF in the Joint Medical Program and holds a Master's in Public Health and a Master's in Health & Medical Sciences from UC Berkeley. Follow at https://x.com/AzadehKhatibiMD 「 SUPPORT OUR SPONSORS 」 • STRONG CELL – If you want to feel more like your younger self, go to https://strongcell.com/ and use code DREW for 20% off. • AUGUSTA PRECIOUS METALS – Thousands of Americans are moving portions of their retirement into physical gold & silver. Learn more in this 3-minute report from our friends at Augusta Precious Metals: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/gold⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or text DREW to 35052 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/drdrew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

What happens when you ask clinicians to hit dozens of quality metrics but never explain why those metrics matter or how to manage them? Kenneth Botelho, founding program director of the Doctor of Medical Science program at the College of St. Scholastica, joins to discuss his KevinMD article, "Value-based care workforce: Bridging the gap in clinical education," and why medical education still trains you to treat one patient at a time in a world that demands population health thinking. He breaks down the disconnect between fee-for-service training and value-based care realities, from dashboard management and HCC coding to compensation tied to screening rates you were never taught to influence. You will hear why this knowledge gap fuels burnout and early career attrition, what PA and NP programs are starting to do about it, and how postgraduate training could give clinicians the framework they need to regain control over their day-to-day work. If you have ever felt graded on a system no one explained to you, this episode will change how you see your role in it. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Did you know that there is clinical evidence showing that collagen peptides may help support joint function, skin and bone health? Join Food Sleuth Radio host and Registered Dietitian, Melinda Hemmelgarn for her conversation with Shiloah Kviatkovsky, PhD, Assistant Professor, Department of Orthopedics, University of Arkansas for Medical Sciences. Kviatkovsky discusses collagen's role in the body, dietary sources of collagen, and what the research shows re the benefits of collagen supplementation.Related Websites:   https://ortho.uams.edu/shiloah-kviatkovsky-ph-d-cissn/

Former Health Ministers Steve Brine and James Bethell dive into the "nihilism" of modern health politics. Is the current strategy just about keeping the NHS out of the headlines, or are we actually making the nation healthier?In this episode:The School Food Revolution: Why Jamie Oliver and Henry Dimbleby might be skeptical of the government's latest "ban" on nuggets.Prostate Cancer Screening: Oliver Kemp (Prostate Cancer Research) explains why the UK is lagging behind Europe and how we can flip the "red to green" on the screening model.The GP Debate: Do GPs need to stop being "country doctors" and start being "risk managers"?Plus, Charlotte Refsum reports from The Academy of Medical Sciences and we hear from:Sir Harpal Kumar, Chief Scientific Officer & President International at GRAIL. Emma Greenwood, AMS Policy Director. Hosted on Acast. See acast.com/privacy for more information.

Welcome to Quick Hits — where we bring you the most impactful moments from past episodes in under 15 minutes. Today's clip comes from one of our most replayed conversations. If you want the full episode, check the link in the description below.   Listen to the full peptide here: https://karenmartel.com/blogs/podcast/unraveling-the-science-of-low-dose-herbal-melatonin-with-deanna-minich    Dr. Deanna Minich, is a Certified Functional Medicine Practitioner, with a Masters of Science degree in Human Nutrition , and a Doctorate in Medical Sciences. She is an international lecturer, educator, and author, with over twenty years of experience in academia and in the food and dietary supplement industries, currently serving as Chief Science Officer at Symphony Natural Health. Through her talks, workshops, groups, and in-person retreats, she helps people to practically and artfully transform their lives through nutrition and lifestyle. Dr. Minich, brings us into the world of melatonin in today's episode, going beyond its well-known role in sleep regulation to explore its lesser-known functions. We discuss how melatonin impacts digestive health, its profound implications for women in menopause, and the influence of nutrients on circadian rhythms. We also examine the controversies surrounding melatonin supplementation, unraveling its powerful antioxidant properties and the importance of finding the right dosage for individual health needs.   Visit her at: www.deannaminich.com.    In this episode: Why understanding melatonin's roles is crucial for women, particularly during menopause. How melatonin production occurs in the pineal gland and the gut. Why nutrient intake affects circadian rhythms and overall health. How irregular schedules can disrupt natural body rhythms, plus solutions to mitigate this. Why it's important to take an individualized approach to nutrient supplementation. How high-dose melatonin may impact the body's systems and hormone balance. Why receptor saturation from high melatonin doses can decrease effectiveness. How melatonin serves as a powerful antioxidant with an appropriate dosage. Why moderation in antioxidant use, including melatonin, is necessary for health. How personalized healthcare helps in understanding supplement and medication interactions. Why melatonin's role extends to the health of bones, joints, the gut, hair, skin, and nails. How lifestyle choices and hormonal balance impact menstrual health. Why melatonin can help manage perimenopausal symptoms like hot flashes and night sweats. How the timing and dosage of melatonin supplementation can be optimized for individual needs. Why continuous adjustments in melatonin intake may be needed as one's health circumstances change.     Sponsors Get 15% off our Progest Sleep oil with coupon sleep.     Are you in perimenopause or postmenopause and struggling with symptoms—but not getting the support you deserve? At Midlife Solutions, we specialize in hormone optimization for women in midlife. Our all-female clinical team offers telehealth care across all 50 U.S. states, with the ability to prescribe bioidentical estrogen, progesterone, testosterone, and thyroid medication.   Book your FREE Hormone Discovery Call Find out what's really driving your symptoms and what your next best steps are.   Visit the website: https://karenmartel.com   Shop the Midlife Solutions Store Over-the-counter bioidentical hormone creams and oils — no prescription needed. Including: • Progesterone • Estrogen Face Cream • Vaginal Moisturizer and more!   Take the Hormone Quiz Discover hidden hormone imbalances that could be driving your symptoms. Get personalized results (and yes, they may surprise you).   Women's Peptide Weight Loss Program Clinically guided, hormone-aware weight loss for midlife women.   Midlife RESET HRT Program A complete, supportive approach to hormone replacement therapy in midlife.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

Limited access to nutritious food can undermine patient treatment and recovery. That's especially true for the often long and arduous recovery many cancer patients face. Vulnerable populations who struggle with social and economic challenges such as food insecurity are at increased risk. Now a program called “Hope for Cancer: Healthy Outcomes Through Produce Prescriptions and Education” is exploring whether healthcare providers can complement a cancer patient's existing treatment by increasing access to healthy, fresh foods through food-as-medicine interventions. To learn more about the program, we're joined on this episode of the Wonks at Work podcast by Dr. Pete DelNero with the University of Arkansas for Medical Sciences.

AI in healthcare is moving fast, but what does real, operational impact actually look like? In this episode, host Sandy Vance chats with Aditya Bansod, CTO and co-founder of Luma Health, and Michelle Winfield-Hanrahan, RN BSN MHA MSN about this very topic. They share how the University of Arkansas for Medical Sciences is scaling AI beyond the call center and into complex, high-friction workflows like fax processing and patient access. From backfilling missed appointments to transforming referral intake, this conversation dives into what it takes to build trust, move quickly, and turn AI into measurable results across an entire health system. In this episode, they talk about: How UAMS identified a high-impact, low-risk entry point for AI in call center workflows Turning after-hours cancellations into filled appointments and improved patient access Why trust in the partner matters just as much as trust in the technology Expanding from AI call handling to backend fax automation How AI is reducing referral lag time and improving data visibility The power of an EHR-first strategy and working inside existing workflows Avoiding “AI sprawl” and the challenge of managing too many point solutions Real talk on ROI: operational efficiency, revenue lift, and happier patients Why success builds momentum for scaling AI across departments Practical advice for health systems navigating the explosion of AI vendors A Little About Aditya and Michelle: Aditya Bansod is CTO and co-founder of Luma Health. With a lifelong passion for building software, Bansod leads Luma Health's technical vision and strategic direction for building a Patient Success Platform that empowers healthcare providers to serve their patients better and improve healthcare outcomes. With over 15 years of experience as a product management leader developing mobile solutions at Adobe and Microsoft, and at venture-backed start-ups, Bansod made the transition from B2B software solutions to healthcare in 2015 to have a meaningful and measurable impact on how providers use mobile technologies to engage with and communicate with their patients.   Michelle Winfield-Hanrahan, RN BSN MHA MSN, is a seasoned healthcare clinical operations executive with over 20 years of experience in optimizing patient access, improving patient engagement, and streamlining clinical operations. Throughout her career, Michelle has demonstrated a strong ability to lead cross-functional teams and implement strategic initiatives that enhance the patient experience, increase operational efficiency, and drive sustainable growth. In her current role as Chief Clinical Access Officer and Associate Vice Chancellor of Access at the University of Arkansas for Medical Sciences, Michelle oversees patient access and flow from both the outpatient and inpatient setting, ensuring seamless patient flow and appointment scheduling, reducing wait times, and improving overall patient satisfaction. She has spearheaded innovative solutions that leverage technology to enhance patient communication and engagement, ensuring that patients remain informed, involved, and empowered throughout their healthcare journey. Michelle is dedicated to driving innovation in healthcare operations and is committed to making quality healthcare more accessible and efficient for all.

With Inga Drossart, ESC Patient Forum, Berlin - Germany, Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia and Vera Maslova, University Medical Center of Schleswig-Holstein, Kiel - Germany. In this podcast, we will talk about patient engagement at two levels: as active partners in their own care and as patient advocates in the healthcare system.

Hatred is one of the most destructive human emotions, responsible for some of the greatest atrocities that humans have committed against each other. But why did it evolve in the first place? What is the evolutionary advantage of hating someone? Why is hate the ‘evil twin' of love? And will we ever be able to ‘treat' hatred and open the door to a utopian world of peaceful coexistence?This lecture was recorded by Robin May on the 4th of March 2026 at Bernard's Inn Hall, LondonProfessor of Infectious Disease at the University of Birmingham, and (interim) Chief Scientist at the UK Health Security Agency, Robin May was appointed Gresham Professor of Physic in May 2022. Between July 2020 and September 2025 he served as Chief Scientific Adviser at the Food Standards Agency (FSA).Professor May's early training was in Plant Sciences at the University of Oxford, followed by a PhD on mammalian cell biology at University College London and the University of Birmingham. After postdoctoral research on gene silencing at the Hubrecht Laboratory, The Netherlands, he returned to the UK in 2005 to establish a research program on human infectious diseases. He was Director of the Institute of Microbiology and Infection at the University of Birmingham from 2017-2020. Professor May continues his work on Infectious Disease at the University of Birmingham. A Fellow of the Academy of Medical Sciences, Wolfson Royal Society Research Merit Fellow and Fellow of the American Academy of Microbiology, Professor May specialises in research into human infectious diseases, with a particular focus on how pathogens survive and replicate within host organisms.As the FSA's Chief Scientific Adviser, Professor May provides expert scientific advice to the UK government and plays a critical role in helping to understand how scientific developments will shape the work of the FSA, as well as the strategic implications of any possible changes.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/why-hateGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Welcome to Health-e Law, Sheppard's podcast exploring the fascinating health tech topics and trends of the day. In this episode, partner and host Michael Orlando welcomes Dr. Newton Howard, founder and CEO of ni2o, to discuss KIWI, the AI-driven brain implant his company is developing. Dr. Howard also shares where he sees this technology taking healthcare in the next decade, and the privacy and ethical considerations surrounding technology with such profound implications for the human mind.   What we discuss in this episode:  How KIWI works and how it uses AI to treat neurological disorders. Why early detection is key to the way ni2o proposes to treat Alzheimer's disease. The impact this technology will have on brain health and healthcare in the next decade. What guardrails should be considered in deploying these technologies. The privacy risks raised by the use of brain tech. Whether these types of devices could be used to manipulate thought or memory. Key considerations for the health industry in the use of brain tech.    About Dr. Newton Howard Dr. Newton Howard is the founder and CEO of ni2o, a neurotechnology company developing AI-powered brain-computer interfaces to treat debilitating neurological disorders and ultimately enhance human cognitive performance. A neuroscientist, inventor and professor, he holds advanced degrees in Mathematics and Neurosurgery from Oxford University and in Cognitive Informatics and Medical Sciences from the Sorbonne.  Dr. Howard's career spans academia, the U.S. military and the private sector, with professorships at Oxford, Georgetown University and MIT, where he directed the Synthetic Intelligence Lab. His foundational scientific contributions—among them the Theory of Intention Awareness, the Fundamental Code Unit and the Brain Code—have opened new pathways in predictive intelligence and the diagnosis and treatment of neurological conditions. His research has made its way into technologies used by millions of people every day, including Wi-Fi hotspots, Google Earth and Google Translate, and he has collaborated extensively with the Department of Defense on advanced defense applications of brain science and AI. Dr. Howard also founded the Howard Brain Sciences Foundation, which funds research in brain disease and neurological treatment, and C4ADS, a data-driven think tank focused on global conflict and transnational security.   About Michael Orlando Michael Orlando is a partner in Sheppard's San Diego (Del Mar) office. He is team leader of the firm's Technology Transactions team, a member of the Life Sciences, Healthcare and Artificial Intelligence teams, and co-leader of the firm's Digital Health & Innovation team. Michael has more than 20 years of experience advising health technology companies, insurers, healthcare systems and providers, academic medical centers and research institutions, medical device manufacturers, pharmaceutical and wellness companies on intellectual property and business transactions in key strategic areas, including EHR systems procurement and integration, telehealth, mobile health applications, clinical decision support technologies, artificial intelligence, data use, wearable devices, remote patient monitoring, medical devices and equipment, research and collaborations, patent licenses, software licenses, joint ventures, mergers and acquisitions, revenue cycle management, and other outsourcing transactions.  Michael founded a software-as-a-service company before entering private practice and completed an in-house secondment at a publicly traded biotechnology company, an experience that informs his practical and business-focused approach to client engagements.   Resources: ni2o   Thank you for listening! Don't forget to SUBSCRIBE to the show to receive new episodes delivered straight to your podcast player every month. If you enjoyed this episode, please help us get the word out about this podcast. Rate and Review this show on Apple Podcasts, Amazon Music, or Spotify. It helps other listeners find this show. This podcast is for informational and educational purposes only. It is not to be construed as legal advice specific to your circumstances. If you need help with any legal matter, be sure to consult with an attorney regarding your specific needs.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Greg Plunkett, Founder and CEO of Accelagen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Greg, covering: How years at big pharma exposed him to the full journey from concept to commercialisation. Why stepping into a smaller organisation gave him the practical tools and confidence to start his own venture. How following market signals into regulatory consulting, while being a stay at home dad, became the foundation for Accelagen. Why trust, referrals and long term relationships have driven sustainable growth. How Australia's clinical trial ecosystem offers quality, speed and tax advantages that attract global innovators. What it takes to guide small to mid sized biotech companies from discovery all the way to market. Greg Plunkett is the Founder and CEO of Accelagen, a full service regulatory affairs and clinical development CRO headquartered in Melbourne, Australia. His career spans almost 30 years across both big and small pharma and biotech organisations before founding Accelagen in 2010. He has supported local and international companies in developing new technologies from discovery through to commercialisation. Greg leads a highly experienced team across Australia, New Zealand and the United States, united by a mission to make a meaningful difference to the future of human health. He holds a Masters of Medical Science from the University of New South Wales and postgraduate business qualifications.   Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

 Dr.Sabhyata Gupta | Chairperson, Gynae-Cology and Gynaec Oncology, Medanta-The Medicity, Gurgaon, ranked as the top private hospital in India  Dr. Sabhyata Gupta is the Chairperson of Gynaecology and Gynae-Oncology at Medanta, Gurugram, and a pioneering figure in her field.She is notably the first gynecologist in India to perform robotic gynaecological surgery for both cancerous and benign conditions.With extensive expertise in robotic surgery, gynaec oncology, colposcopy, advanced gynaec laparoscopy, and hysteroscopy, Dr. Gupta is a leader in providing cutting-edge treatments for women's health.Her qualifications include an MD in Gynecology, specialized training in Robotic Gynaecological Surgery, a Diploma in Gynaecological Endoscopic Surgery, and advanced training in uro-gynaecological oncology.She has also completed the Indo-German Training Course in Advanced Endoscopic Surgery in Gynecology.Dr. Gupta has received numerous accolades, including the prestigious ‘Arch of Excellence Award (Medicare)' at the All India Achievers' Conference in 2009.She is an esteemed member of several renowned organizations, including the International Gynaecological Cancer Society, the European Society of Gynaecological Oncology, the Federation of Obstetrics & Gynaecological Societies of India, and the Indian Medical Association.Specializing in Gynecologic Oncology, Dr. Gupta possesses profound expertise in a wide array of procedures such as:Robotic Gynecological SurgeryAdvanced Gynecological LaparoscopyHysteroscopyColposcopyWAwards & Recognitions Dr. Sabhyata Gupta has received numerous awards for her work and contribution to Medical Science. The most remarkable awards are-She won the Bharat Jyoti Award from the “India International Friendship Society” in Delhi in 2009.In 2009, she was facilitated with the Bharat Excellence Award & Gold Medal by the “Friendship Forum of India”, in Delhi.In the same year itself, she was conferred with the Gold Medal for the Rising Personalities of India by “The International Penguin Publishing House” in Delhi.She also won the Gold Award in the category Pride of India from the house of “Friendship Forum Of India” in Delhi in 2009.Last but not the least, she won the Arch of Excellence Award (Medicare) at the All India Achievers conference in Delhi in 2009.  

In this episode of CURiE Conversations on the ACRO Podcast, Dr. Veronia Fahmy speaks with author Dr. Ricky Savjani about his published article, “A Silicone-Based Film-Forming Gel Wound Dressing for Radiation Dermatitis in Head and Neck Cancer Patients: A Retrospective Cohort Analysis Using Clinical Informatics.”Contemporary Updates: Radiotherapy Innovation & Evidence (CURiE) is the official publication platform of the American College of Radiation Oncology through the Cureus Journal of Medical Science. Read the full article here: https://www.cureus.com/articles/421775-a-silicone-based-film-forming-gel-wound-dressing-for-radiation-dermatitis-in-head-and-neck-cancer-patients-a-retrospective-cohort-analysis-using-clinical-informatics#!/

(0:00) Intro(0:02) Khutba – Tafseer Surah Mulk(0:47) Surah Mulk ki Eham Aayat(1:10) Ramazan ka Ikhtitam – Fikr ka Lamha(2:27) Ex-Christian Interview (Canada)(3:36) Umar (RA) ka Qoul(4:04) Qur'an ki Misal(4:51) Insan ki Pedaish – Aazmaish(5:26) Scientific Takabbur(6:40) Qur'an ki Guidance(7:51) Insan ka Maqsad(8:08) Achay Amal ki Definition(9:01) Ehl-e-Imaan(9:12) Allah ki Sifaat – Aziz, Ghafoor(9:52) 7 Aasman aur Kaainat(12:03) Kaainat ke Ajaaib(13:08) Space aur Black Hole(13:48) Allah ki Takhleeq(14:20) Barish ka Nizam(15:16) Allah ka Challenge(16:51) Medical Science aur Mufti Sahab(17:25) Dozakh ka Zikr(17:54) Dozakh ka Jalal(18:37) Dozakhiyon se Sawal(19:25) Atheists Speeches(20:15) Jannat vs Dozakh Concept(21:07) Allah ki Rehmat vs Ghazab(21:58) Dozakhiyon ka Afsos(22:27) Jannat – Iman bil Ghaib ka Badla(23:25) Allah ka Ilm(23:43) Surah Najm ka Saboot(25:01) Tazkiya(26:02) Zameen ke Khazanay(27:59) Rizq aur Export(28:47) Rizq Allah ke Zimme(30:25) Aaj ka Rizq(31:47) Allah ka Khauf(32:28) Sitaron ka Nizam(32:48) Jupiter ki Power(33:11) Farishtay aur Jinn(34:15) Gas Bills(34:46) Allah ka Kamal(35:26) Allah ke Dalail(36:50) Scientist ka Iqraar(37:46) Parinday vs Jahaz(38:52) Machhar ki Takhleeq(39:38) Machhar ka System(40:47) Micro Organisms(41:04) Allah ki Qudrat(41:20) Kafir ki Misal(41:58) Nashukra Insan(42:14) Pani ka Nizam(44:39) Meetha Pani(46:29) Pani band hone ka Khauf(46:37) Surah Haqqah – Jannat(46:43) Daain Hath walay(47:26) Hisab se Pehle(47:56) Jannati Zindagi(48:48) Jannat ke Phal(49:17) Baain Hath walay(50:00) Dozakhiyon ka Jurm(50:38) Makhlooq ka Haq(51:44) Khana Khilana(52:29) Ghareeb ka Haq(53:22) Miskin ka Sawab(53:44) Zaqqoom(53:58) Aakhri Bayan Announcement(54:05) Qur'an Shaer ka Kalam nahi(54:24) Sheh Rag wali Aayat(55:32) Nabuwwat ki Daleel(57:25) Jhootay Daawedaron ka Anjam(58:13) Mirza Ghulam Ahmed Qadiani(58:49) Nabuwwat ki Toheen(59:52) Nabuwwat ki Daleel(1:00:28) Qadianiyat ki Haqeeqat(1:01:24) Class Fellow Waqia(1:01:42) Toheen-e-Risalat(1:02:29) Jhootay Daaway(1:03:07) Character(1:04:20) Challenge(1:04:48) Kitaben(1:05:15) Peshgoiyan(1:05:30) Muhammadi Begum Case(1:05:52) Canada Meeting(1:06:31) Jhooti Peshgoi ka Jawab(1:08:45) Qadianiyat ka Radd(1:09:29) Nabi ﷺ ki Shan(1:10:05) Dua Hosted on Acast. See acast.com/privacy for more information.

Want to Be the Best Version of Yourself? Sign Up Here.https://app.beerbiceps.com/web/checkout/699d46a79b98fa69b168b402Check out BeerBiceps SkillHouse Courses Here - https://www.bbskillhouse.comFor all BeerBiceps vlog content Watch Life Of BeerBiceps - https://www.youtube.com/@LifeOfBeerBicepsCheck out my Mind Performance app: Level SuperMindLink:- https://level4665.u9ilnk.me/d/F1ZOZV4OnTShare your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9Join the Level Community Here:https://linktr.ee/levelsupermindcommunityFollow BeerBiceps SkillHouse's Social Media Handles:YouTube: https://www.youtube.com/@BeerBicepsSkillHouseInstagram: https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comFollow Dr. Jatin Shah's Social Media Handles:-LinkedIn: https://in.linkedin.com/in/drjatinshahWebsite: https://drjatinshah.com/In this highly educational episode 478th of The Ranveer Show, we are joined by top IVF specialist Dr. Jatin Shah, who shares deep insights on Reproductive Health, IVF (In Vitro Fertilization), Infertility, Family Planning, and important Biological Facts.In this conversation with Dr. Jatin Shah, we talk about the crucial topic of Egg Freezing, the right fertile window to conceive, Male Infertility, Sperm Health, and the harmful effects of smoking, vaping, and steroids on fertility. This episode also covers the difference between natural and IVF babies, the reasons behind miscarriages, the reality of twin pregnancies, the concept of Epigenetics, and the importance of timely AMH testing for young women. This podcast is a valuable resource for anyone interested in Sexual Health Education, Family Planning, Understanding IVF, Human Biology, Personal Well-being, and Medical Science. (00:00) – Start of the episode(03:07) – IVF Myths & Celebrity Cases(05:06) – The Reality of Sperm Donation(09:20) – Egg Freezing Explained(15:12) – Having Kids at 60?(21:09) – Why Do IVF Cycles Fail?(23:40) – M*sturbation & Male Infertility(28:56) – The Right Time to Have S*x(34:45) – Foods to Boost Fertility(37:02) – Smoking, Vaping & Fertility Damage(42:27) – Emergency Pills & Abortion Side Effects(52:22) – Miscarriages & Fertility Supplements(56:42) – Gym Steroids Destroying Sperm(01:01:59) – Can Sperm Get Mixed Up?(01:03:57) – How Painful is Egg Freezing?(01:13:05) – Epigenetics & Garbh Sanskar(01:15:16) – Pollution is Killing Sperm Counts(01:17:20) – The PCOS & Weight Gain Epidemic(01:22:36) – Are Twins Actually Dangerous?(01:26:33) – End of the episode

Dean's Chat hosts, Drs. Jensen and Richey welcome Madelin C. Ramil, DPM, FACFAS, to the podcast. Dr. Ramil is Dean and Professor at Barry University School of Podiatric Medicine (College of Health Professions & Medical Sciences) and a foot and ankle surgeon. She leads clinical education, accreditation and continuous quality improvement, curriculum and assessment, and student advising, retention, and board readiness, while expanding clinical training partnerships. This episode is spoonsorted by Bako Diagnostics!Dr. Ramil earned her DPM from Barry University. She completed residency training at Florida Medical Center North and Plantation General Hospital and pursued fellowship training at Hospital San Rafael in Barcelona, Spain, and in Rome, Italy, under Dr. Ronconi. She is licensed in Florida and is a Fellow of the American College of Foot and Ankle Surgeons. With more than 25 years in practice, Dr. Ramil has trained residents and externs as an attending physician and served as Assistant Surgical Foot and Ankle Residency Program Director. She directed the Foot and Ankle Clinic at Plantation General Hospital and has held privileges in multiple Broward County hospitals. A wound care expert, she has provided care in hospital-based wound centers across South Florida. A national and international speaker, Dr. Ramil also teaches foot surgery in Spain. She served as Director of Research for the HCA Westside Hospital Podiatric Medicine and Surgery Residency Program, supporting clinically relevant scholarship and educational quality initiatives. A proud Barry alumnus, she participated for over 15 years in the Dr. Charles Southerland Yucatán Crippled Children's Program, BUSPM's sponsored medical mission.

In this episode, Peter will talk to us about the Woodford Folk Festival, where the ATMS sponsored a tent of homeopaths to help out at the six day and six  night event, where they treated a whole variety of different conditions. Peter Berryman is a qualified Naturopath, Homeopath, Medical Scientist & educator who has spent 30 years+ in clinical practice. Peter is also Director (2007-) and President (2017 -) of the ATMS, with the special role of representing the ATMS on the Chinese Medical Board of NSW, the Australia Council of Chinese Medicine, and the Chinese Medical Board of Australia. He holds a Master of Science (homeopathy), a Bachelor of Medical Science, a Bachelor of Science, a post-graduate diploma in health sciences, an advanced diploma in homeopathy, a diploma in naturopathy, and a post-graduate diploma in education, and a graduate of the Australian Institute of Company Directors. Check out these episode highlights: 01:54 - What is the Woodford Folk Festival 08:06 - How the festival is different from other festivals 15:00 - What is the experience like at the dispensary 19:03 - Fibonacci home records in water dosing 32:14 - Where can people get in touch if they want to get involved 35:55 - The future of homeopathy in Australia 45:54 - How long does it take for chronic cases to reach the point of cure Find out more about Peter Website: https://www.atms.com.au/ If you would like to support the Homeopathy Hangout Podcast, please consider making a donation by visiting www.EugenieKruger.com and click the DONATE button at the top of the site. Every donation about $10 will receive a shout-out on a future episode.   Join my Homeopathy Hangout Podcast Facebook community here: https://www.facebook.com/groups/HelloHomies Follow me on Instagram https://www.instagram.com/eugeniekrugerhomeopathy/   Here is the link to my free 30-minute Homeopathy@Home online course: https://www.youtube.com/watch?v=vqBUpxO4pZQ&t=438s   Upon completion of the course - and if you live in Australia - you can join my Facebook group for free acute advice (you'll need to answer a couple of questions about the course upon request to join): www.facebook.com/groups/eughom

PainExam Podcast Show Notes Red Light Therapy (Photobiomodulation) for Pain Evidence, Mechanisms, and Clinical Applications Host: Dr. David Rosenblum Red light therapy, also known as photobiomodulation (PBM) or low-level laser therapy (LLLT), is an emerging non-invasive treatment modality increasingly used in pain medicine, rehabilitation, and regenerative medicine practices. In this episode of the PainExam Podcast, Dr. Rosenblum reviews the mechanisms, clinical evidence, indications, and safety considerations surrounding photobiomodulation therapy for pain. Red and near-infrared wavelengths stimulate mitochondrial activity, increase ATP production, reduce inflammatory mediators, and promote tissue healing. These physiologic effects may translate into analgesic benefits for a variety of musculoskeletal and neuropathic pain conditions. Clinical research suggests potential benefit in temporomandibular disorders, chronic neck pain, and inflammatory oral conditions, though results vary due to differences in dosing parameters and treatment protocols. Despite these limitations, PBM has a favorable safety profile and is increasingly being integrated into multimodal pain management strategies. Key Topics Covered • What is photobiomodulation therapy (PBM) • How red and near-infrared light interact with mitochondria • Mechanisms of analgesia and tissue repair • Evidence from clinical trials in TMD, neck pain, and oral inflammatory pain • The biphasic dose response (Arndt-Schulz law) • Safety profile and contraindications • How PBM may integrate with regenerative pain medicine Mechanism of Action Photobiomodulation works primarily through stimulation of mitochondrial chromophores, particularly cytochrome c oxidase. This leads to: • Increased ATP production • Modulation of inflammatory cytokines • Increased angiogenesis and tissue repair • Reduced oxidative stress These effects may improve pain, inflammation, and healing in certain musculoskeletal conditions. Evidence Discussed in This Episode Temporomandibular Disorders Randomized trial demonstrating improvements in pain and mandibular function with red light therapy. De Carvalho et al., Pain Research and Treatment (2019) https://onlinelibrary.wiley.com/doi/full/10.1155/2019/8578703 Chronic Neck Pain Clinical trial demonstrating improvements in pain scores and pressure pain thresholds after photobiomodulation therapy. Chen et al., Lasers in Medical Science (2022) https://link.springer.com/article/10.1007/s10103-022-03540-0 Oral Pain and Dental Inflammation Randomized study demonstrating reduced pain and improved healing following PBM treatment. Almeida et al., BMC Oral Health (2023) https://link.springer.com/article/10.1186/s12903-023-02784-8 Who May Benefit From Photobiomodulation? Red light therapy may be considered as an adjunct treatment for: • myofascial pain • cervical spine pain • temporomandibular disorder • tendinopathy • peripheral neuropathy • musculoskeletal injury recovery Safety and Contraindications Photobiomodulation has a very favorable safety profile. Reported adverse effects are rare and usually mild: • transient erythema • warmth at treatment site • headache • eye irritation without proper protection Precautions include: • avoiding direct retinal exposure • avoiding treatment over malignancy • avoiding application over the uterus during pregnancy • caution in photosensitive disorders Resources For Patients Seeking Treatment Learn more about integrative and regenerative pain treatments including PRP, ultrasound-guided injections, and advanced pain therapies: AABP Integrative Pain Care & Wellness https://www.AABPpain.com For Pain Physicians and Advanced Practice Providers Training in ultrasound, interventional pain procedures, and pain board preparation: NRAP Academy CME Education https://www.NRAPpain.org

PainExam Podcast Show Notes Red Light Therapy (Photobiomodulation) for Pain Evidence, Mechanisms, and Clinical Applications Host: Dr. David Rosenblum Red light therapy, also known as photobiomodulation (PBM) or low-level laser therapy (LLLT), is an emerging non-invasive treatment modality increasingly used in pain medicine, rehabilitation, and regenerative medicine practices. In this episode of the PainExam Podcast, Dr. Rosenblum reviews the mechanisms, clinical evidence, indications, and safety considerations surrounding photobiomodulation therapy for pain. Red and near-infrared wavelengths stimulate mitochondrial activity, increase ATP production, reduce inflammatory mediators, and promote tissue healing. These physiologic effects may translate into analgesic benefits for a variety of musculoskeletal and neuropathic pain conditions. Clinical research suggests potential benefit in temporomandibular disorders, chronic neck pain, and inflammatory oral conditions, though results vary due to differences in dosing parameters and treatment protocols. Despite these limitations, PBM has a favorable safety profile and is increasingly being integrated into multimodal pain management strategies. Key Topics Covered • What is photobiomodulation therapy (PBM) • How red and near-infrared light interact with mitochondria • Mechanisms of analgesia and tissue repair • Evidence from clinical trials in TMD, neck pain, and oral inflammatory pain • The biphasic dose response (Arndt-Schulz law) • Safety profile and contraindications • How PBM may integrate with regenerative pain medicine Mechanism of Action Photobiomodulation works primarily through stimulation of mitochondrial chromophores, particularly cytochrome c oxidase. This leads to: • Increased ATP production • Modulation of inflammatory cytokines • Increased angiogenesis and tissue repair • Reduced oxidative stress These effects may improve pain, inflammation, and healing in certain musculoskeletal conditions. Evidence Discussed in This Episode Temporomandibular Disorders Randomized trial demonstrating improvements in pain and mandibular function with red light therapy. De Carvalho et al., Pain Research and Treatment (2019) https://onlinelibrary.wiley.com/doi/full/10.1155/2019/8578703 Chronic Neck Pain Clinical trial demonstrating improvements in pain scores and pressure pain thresholds after photobiomodulation therapy. Chen et al., Lasers in Medical Science (2022) https://link.springer.com/article/10.1007/s10103-022-03540-0 Oral Pain and Dental Inflammation Randomized study demonstrating reduced pain and improved healing following PBM treatment. Almeida et al., BMC Oral Health (2023) https://link.springer.com/article/10.1186/s12903-023-02784-8 Who May Benefit From Photobiomodulation? Red light therapy may be considered as an adjunct treatment for: • myofascial pain • cervical spine pain • temporomandibular disorder • tendinopathy • peripheral neuropathy • musculoskeletal injury recovery Safety and Contraindications Photobiomodulation has a very favorable safety profile. Reported adverse effects are rare and usually mild: • transient erythema • warmth at treatment site • headache • eye irritation without proper protection Precautions include: • avoiding direct retinal exposure • avoiding treatment over malignancy • avoiding application over the uterus during pregnancy • caution in photosensitive disorders Resources For Patients Seeking Treatment Learn more about integrative and regenerative pain treatments including PRP, ultrasound-guided injections, and advanced pain therapies: AABP Integrative Pain Care & Wellness https://www.AABPpain.com For Pain Physicians and Advanced Practice Providers Training in ultrasound, interventional pain procedures, and pain board preparation: NRAP Academy CME Education https://www.NRAPpain.org

PainExam Podcast Show Notes Red Light Therapy (Photobiomodulation) for Pain Evidence, Mechanisms, and Clinical Applications Host: Dr. David Rosenblum Red light therapy, also known as photobiomodulation (PBM) or low-level laser therapy (LLLT), is an emerging non-invasive treatment modality increasingly used in pain medicine, rehabilitation, and regenerative medicine practices. In this episode of the PainExam Podcast, Dr. Rosenblum reviews the mechanisms, clinical evidence, indications, and safety considerations surrounding photobiomodulation therapy for pain. Red and near-infrared wavelengths stimulate mitochondrial activity, increase ATP production, reduce inflammatory mediators, and promote tissue healing. These physiologic effects may translate into analgesic benefits for a variety of musculoskeletal and neuropathic pain conditions. Clinical research suggests potential benefit in temporomandibular disorders, chronic neck pain, and inflammatory oral conditions, though results vary due to differences in dosing parameters and treatment protocols. Despite these limitations, PBM has a favorable safety profile and is increasingly being integrated into multimodal pain management strategies. Key Topics Covered • What is photobiomodulation therapy (PBM) • How red and near-infrared light interact with mitochondria • Mechanisms of analgesia and tissue repair • Evidence from clinical trials in TMD, neck pain, and oral inflammatory pain • The biphasic dose response (Arndt-Schulz law) • Safety profile and contraindications • How PBM may integrate with regenerative pain medicine Mechanism of Action Photobiomodulation works primarily through stimulation of mitochondrial chromophores, particularly cytochrome c oxidase. This leads to: • Increased ATP production • Modulation of inflammatory cytokines • Increased angiogenesis and tissue repair • Reduced oxidative stress These effects may improve pain, inflammation, and healing in certain musculoskeletal conditions. Evidence Discussed in This Episode Temporomandibular Disorders Randomized trial demonstrating improvements in pain and mandibular function with red light therapy. De Carvalho et al., Pain Research and Treatment (2019) https://onlinelibrary.wiley.com/doi/full/10.1155/2019/8578703 Chronic Neck Pain Clinical trial demonstrating improvements in pain scores and pressure pain thresholds after photobiomodulation therapy. Chen et al., Lasers in Medical Science (2022) https://link.springer.com/article/10.1007/s10103-022-03540-0 Oral Pain and Dental Inflammation Randomized study demonstrating reduced pain and improved healing following PBM treatment. Almeida et al., BMC Oral Health (2023) https://link.springer.com/article/10.1186/s12903-023-02784-8 Who May Benefit From Photobiomodulation? Red light therapy may be considered as an adjunct treatment for: • myofascial pain • cervical spine pain • temporomandibular disorder • tendinopathy • peripheral neuropathy • musculoskeletal injury recovery Safety and Contraindications Photobiomodulation has a very favorable safety profile. Reported adverse effects are rare and usually mild: • transient erythema • warmth at treatment site • headache • eye irritation without proper protection Precautions include: • avoiding direct retinal exposure • avoiding treatment over malignancy • avoiding application over the uterus during pregnancy • caution in photosensitive disorders Resources For Patients Seeking Treatment Learn more about integrative and regenerative pain treatments including PRP, ultrasound-guided injections, and advanced pain therapies: AABP Integrative Pain Care & Wellness https://www.AABPpain.com For Pain Physicians and Advanced Practice Providers Training in ultrasound, interventional pain procedures, and pain board preparation: NRAP Academy CME Education https://www.NRAPpain.org

With Wolfram Doehner, Charite University Hospital, Berlin - Germany, Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia and Jacopo Francesco Imberti, Modena Polyclinic Modena University Hospital, Modena - Italy. This podcast episode will tackle AF burden, clinical implications and association of AF burden with clinical outcomes.

Before he was even born, Sarah and Ross Gray knew that their son Thomas wouldn't live long. But as they let go of him, they made a decision that reverberated through a world that they never bothered to think about. Years later, after a couple of awkward phone calls, they go on a quest and manage to meet the people and places for whom Thomas' short life was an altogether different kind of gift. We originally made this story back in 2015, but we wanted to play it again because we love that it brings a view of science that is redemptive, tender, and unexpected. Since we first released this episode, Sarah Gray wrote a book called A Life Everlasting (https://zpr.io/GVYisRaqe9d6), it's a memoir about Thomas that dives into the world of organ donation and medical science. She's also written a beautiful short story about shame called The Lacemaker Fairy Tale (https://zpr.io/Li5BMtfHmf92). And, right now she's working on a script for a movie called Raincheck.EPISODE CREDITS: Reported by - Jad Abumrad with help from - Latif NasserLATERAL CUTS - The Cathedral (https://radiolab.org/podcast/cathedral) The Immortal Life of Henrietta Lacks (https://radiolab.org/podcast/the-immortal-life-of-henrietta-lacks)  Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org. Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

The gap between vaccine science and vaccine policy has been widening under Health Secretary Robert F. Kennedy Jr. Now, the American Medical Association and the Vaccine Integrity Project, based at the University of Minnesota, have announced that they are partnering to create their own vaccine review process, effectively creating a parallel system to the CDC's. Host Ira Flatow talks with Michael Osterholm, executive director of the Vaccine Integrity Project, about the role of this new review panel.Guest: Dr. Michael Osterholm is the director of the Center for Infectious Disease Research and Policy and executive director of the Vaccine Integrity Project at the University of Minnesota.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

The use of stimulants during WWII is no secret, but in the last decade, there has been a lot of discussion and analysis of it. Just how significant was drug use in Nazi Germany, and how did the Allies compare? Research: Ackermann, Paul. “Les soldats nazis dopés à la méthamphétamine pour rester concentrés.” HuffPost France. June 4, 2013. https://www.huffingtonpost.fr/actualites/article/les-soldats-nazis-dopes-a-la-methamphetamine-pour-rester-concentres_19714.html Andreas, Peter. “How Methamphetamine Became a Key Part of Nazi Military Strategy.” Time. Jan. 7, 2020. https://time.com/5752114/nazi-military-drugs/ Blakemore, Erin. “A Speedy History of America’s Addiction to Amphetamine.” Smithsonian. Oct. 27, 2017. https://www.smithsonianmag.com/history/speedy-history-americas-addiction-amphetamine-180966989/ Boeck, Gisela, and Vera Koester. “Who Was the First to Synthesize Methamphetamine?” Chemistry Views. https://www.chemistryviews.org/9-who-first-synthesized-methamphetamine/ “Ephedra.” National Center for Complementary and Integrative Health.” https://www.nccih.nih.gov/health/ephedra Eghigian, Greg, PhD. “A Methamphetamine Dictatorship? Hitler, Nazi Germany, and Drug Abuse.” Psychiatric Times. June 23, 2016. https://www.psychiatrictimes.com/view/methamphetamine-dictatorship-hitler-nazi-germany-and-drug-abuse Garber, Megan, “‘Pilot’s Salt’: The Third Reich Kept Its Soldiers Alert With Meth.” The Atlantic. May 31, 2013. https://www.theatlantic.com/technology/archive/2013/05/pilots-salt-the-third-reich-kept-its-soldiers-alert-with-meth/276429/ Gifford, Bill. “The Scientific AmericanGuide to Cheating in the Olympics.” Scientific American. August 5, 2016. https://www.scientificamerican.com/article/the-scientific-american-guide-to-cheating-in-the-olympics/ Gorvett, Zaria. “The Drug Pilots Take to Stay Awake.” BBC. March 14, 2024. https://www.bbc.com/future/article/20240314-the-drug-pilots-take-to-stay-awake Grinspoon, Lester. “The speed culture : amphetamine use and abuse in America.” Harvard University Press. 1975. Accessed online: https://archive.org/details/speedcultureamph0000grin_n3i0/mode/1up Gupta, Raghav et al. “Understanding the Influence of Parkinson Disease on Adolf Hitler's Decision-Making during World War II.” World Neurosurgery. Volume 84, Issue 5. 2015. Pages 1447-1452. https://doi.org/10.1016/j.wneu.2015.06.014. Hurst, Fabienne. “The German Granddaddy of Crystal Meth.” Spiegel. Dec. 23, 2013. https://www.spiegel.de/international/germany/crystal-meth-origins-link-back-to-nazi-germany-and-world-war-ii-a-901755.html Isenberg, Madison. “Volksdrogen: The Third Reich Powered by Methamphetamine.” The Macksey Journal. University of Texas at Tyler. Volume 4, Article 21. 2023. https://scholarworks.uttyler.edu/cgi/viewcontent.cgi?article=1001&context=senior_projects Laskow, Sarah. “Brewing Bad: The All-Natural Origins of Meth.” The Atlantic. Oct. 3, 2014. https://www.theatlantic.com/technology/archive/2014/10/brewing-bad-the-all-natural-origins-of-meth/381045/ Lee, Ella. “Fact check: Cocaine in Coke? Soda once contained drug but likely much less than post claims.” USA Today. July 25, 2021. https://www.usatoday.com/story/news/factcheck/2021/07/25/fact-check-coke-once-contained-cocaine-but-likely-less-than-claimed/8008325002/ Leite, Fagner Carvalho et al. “Curine, an alkaloid isolated from Chondrodendron platyphyllum inhibits prostaglandin E2 in experimental models of inflammation and pain.” Planta medica 80,13 (2014): 1072-8. doi:10.1055/s-0034-1382997 Meyer, Ulrich. “Fritz hauschild (1908-1974) and drug research in the 'German Democratic Republic' (GDR).” Die Pharmazie 60 6 (2005): 468-72. Natale, Fabian. “Pervitin: how drugs transformed warfare in 1939-45.” Security Distillery. May 6, 2020. https://thesecuritydistillery.org/all-articles/pervitin-how-drugs-transformed-warfare-in-1939-45 Ohler, Norman. “Blitzed: Drugs in the Third Reich.” Houghton Mifflin Harcourt. 2017. Rasmussen, Nicolas. “Medical Science and the Military: The Allies’ Use of Amphetamine during World War II.” The Journal of Interdisciplinary History, vol. 42, no. 2, 2011, pp. 205–33. JSTOR, http://www.jstor.org/stable/41291190 “Reich Minister of Health Dr. Leonardo Conti Speaks with Hitler’s Personal Physician, Dr. Karl Brandt (August 1, 1942).” German History in Documents and Images. https://germanhistorydocs.org/en/nazi-germany-1933-1945/reich-minister-of-health-dr-leonardo-conti-speaks-with-hitler-s-personal-physician-dr-karl-brandt-august-1-1942 Schwarcz, Joe. “The Right Chemistry: Once a weapon, methamphetamine is now a target.” Oct. 1, 2021. https://montrealgazette.com/opinion/columnists/the-right-chemistry-once-a-weapon-methamphetamine-is-now-a-target Snelders, Stephen and Toine Pieters. “Speed in the Third Reich: Metamphetamine (Pervitin) Use and a Drug History From Below.” Social History of Medicine. Volume 24, Issue 3. December 2011. Pages 686–699. https://doi.org/10.1093/shm/hkq101 “Stimulant Pervitin.” Deutschland Museum. https://www.deutschlandmuseum.de/en/collection/stimulant-pervitin/ Tinsley, Grant. “Ephedra (Ma Huang): Weight Loss, Dangers, and Legal Status.” Helthline. March 14, 2019. https://www.healthline.com/nutrition/ephedra-sinica See omnystudio.com/listener for privacy information.

Host John Beckner is joined by Ed Cohen, founder and COO of PharmTeam Associates, and Megan Smith, PharmD, director of the UAMS Community-Based Residency Program and associate professor at the University of Arkansas for Medical Sciences, to explore how community pharmacy has evolved, and why no two community pharmacies are the same.

Tony: -Carbonation Station: Lando Reviews Lando!   -More Autonomous Lies: https://www.techspot.com/news/111233-waymo-admits-autopilot-often-guys-philippines.html   -Trump Phone situation continues to amaze: https://www.engadget.com/mobile/smartphones/trump-mobiles-t1-phone-is-apparently-still-coming-but-itll-be-uglier-and-more-expensive-190626835.html   -Another possibly awesome BT option: https://www.audioreviews.org/noble-announces-sceptre/   -The FDA continues to circle the drain: https://arstechnica.com/health/2026/02/fda-refuses-to-review-modernas-mrna-flu-vaccine/   -Snapmaker U1 has arrived!   Jarron:  -Tesla is canceling Model S and Model X https://www.cnn.com/2026/01/28/business/tesla-q4-2025-earnings   -Sodium Ion batteries incoming: The World's First Sodium-Ion Battery in Commercial EVs - Great at Low Temperatures   -Biohacking to get ahead at the Olympics: https://arstechnica.com/health/2026/02/penisgate-erupts-at-olympics-scandal-exposes-risks-of-bulking-your-budge/   -Rivian R2 shown off https://www.theverge.com/transportation/876441/the-early-reviews-of-the-rivian-r2-are-starting-to-roll-in   Owen: -Discord cracking down https://www.theverge.com/tech/875309/discord-age-verification-global-roll-out -Discord Clarification: https://discord.com/press-releases/discord-launches-teen-by-default-settings-globally Lando:   -AI Ads https://techcrunch.com/2026/02/09/chatgpt-rolls-out-ads/   -Fart Tech https://gizmodo.com/how-many-times-do-you-fart-a-day-smart-underwear-says-its-way-more-than-you-think-2000719805

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

Send us a textFebruary is National Heart Month, and in the month of hearts, we're revisiting one of the most important conversations from the Ageless Glamour Girls™ Podcast archives.Broken Heart Syndrome can mimic the symptoms of a heart attack - and it can occur after sudden, intense emotional or physical stress. Research shows cases are increasing, particularly among middle-aged and older women. This episode originally aired during our debut season in March 2022, but its message feels even more urgent today. We're joined by Dr. Susan Cheng, senior author of a major study on the condition and a leading cardiologist at the Smidt Heart Institute at Cedars-Sinai. Dr. Cheng breaks down:What Broken Heart Syndrome is - and what it isn'tWhy women are disproportionately affectedThe powerful role stress plays in heart healthAnd, most importantly, why this condition is treatableIf you've ever felt the physical weight of emotional stress, this conversation matters. And here's to Healthy Aging and Joyful Living, Luvvies!**********************GUEST BIO: Susan Cheng, MD, MMSc, MPH is the Erika J. Glazer Chair in Cardiovascular Health and Population Science, Director of the Institute for Research on Healthy Aging, and Director of Population Health Sciences at the Smidt Heart Institute at Cedars-Sinai. She also serves as Professor and Vice Chair of Research Affairs in the Department of Cardiology. Dr. Cheng is a cardiologist, echocardiographer, and clinician-scientist who leads nationally recognized research programs focused on the drivers of cardiovascular aging in women and men. She received her bachelor's degree from Harvard College, her medical degree from McMaster University, a Master of Medical Science from MIT, and a Master of Public Health from Harvard.She completed internal medicine training at The Johns Hopkins Hospital and cardiology training at Brigham and Women's Hospital and Harvard Medical School, where she later served as cardiology faculty and Associate Director of the Cardiovascular Imaging Core Laboratory. Dr. Cheng is also Co-Director of the Framingham Heart Study Echocardiography Laboratory and Co-Director of the international Bioactive LipidsNet Consortium. She has served on editorial boards of major cardiovascular and imaging journals and on leadership committees for the American Heart Association and the American College of Cardiology. Dr. Cheng has chaired and contributed to multiple American Heart Association scientific statements on research methods, heart disease statistics, and cardiovascular care of older adults. She has authored more than 4Support the show https://buymeacoffee.com/agelessglamourgirls www.linkedin.com/in/marqueetacurtishaynes www.agelessglamourgirls.com https://www.shopltk.com/explore/AgelessGlamourGirls https://www.youtube.com/@agelessglamourgirls Instagram @agelessglamourgirls Facebook: https://www.facebook.com/agelessglamourgirls Private (AGG) FB Group: The Ageless Café: https://www.facebook.com/groups/theagelesscafe TikTok: @agelessglamourgirls Podcast Producers: Ageless Glamour Girls and Purple Tulip Media, LLC

Matthew David and Randy Olson have a preliminary discussion of David H Freedman's 2010 Atlantic article, "Lies, Damned Lies, and Medical Science."  We work on our 3 questions each that we'll be asking David to start the discussion.  Please join us on Wednesday, Feb 11th, 10:00 am PST, RSVP here:  https://www.eventbrite.com/e/adventures-in-medical-misinformation-two-cases-of-misperception-tickets-1980404588435?aff=oddtdtcreator   Randy Olson https://x.com/ABTagenda Randy's Blog: https://abtagenda.substack.com/ Learn more about the ABT Framework Course: http://abtnarrative.com/

What happens when a health system stops trying to recruit its way out of a workforce challenge, and instead redesigns the pipeline itself? In this episode of Bright Spots in Healthcare, Eric Glazer sits down with Dr. Lindsay Mazotti, Chief Medical Officer of Medical Science and Education at Sutter Health, for a candid, system-level conversation about rethinking how physicians are trained, supported, and developed for the future of care. Rather than focusing on workforce shortages as a policy or awareness problem, this conversation explores what happens after the reality is already clear—when leaders choose to redesign foundational systems instead of managing around constraints. Dr. Mazotti shares how Sutter is treating graduate medical education as strategic infrastructure, not an academic side function, and what it takes to build a physician pipeline that can scale, adapt, and endure. Using examples from rural training pathways, academic partnerships, research translation, and digital transformation, the discussion surfaces how education becomes the load-bearing structure that allows health systems to absorb change without breaking. This episode is designed for health system leaders who are no longer asking whether change is needed, but are grappling with how to build systems that can carry what's coming next. In this episode, we cover: Why physician shortages can't be solved through recruiting alone How Sutter is redesigning the physician pipeline end to end What changes when graduate medical education is treated as core infrastructure How training clinicians for place shapes rural and underserved care delivery Why education is the missing link between research, digital innovation, and day-to-day care Where clinician training determines adoption—or abandonment—of new technologies The leadership tradeoffs that come with moving from individual patient care to system-level impact What leaders must unlearn when building durable, long-term capability About Dr. Lindsay Mazotti: Dr. Lindsay Mazotti leads system-wide initiatives at Sutter Health that advance medical education, research, and innovation in support of the organization's mission to deliver exceptional, patient-centered care to more than 3 million patients across 22 counties in Northern California. In her role, she focuses on strategically integrating medical education into the health system's infrastructure to align with long-term priorities, including Sutter's Destination 2030 initiative. Dr. Mazotti oversees undergraduate and graduate medical education across the system—spanning clinical rotations, scholarships, residency and fellowship programs, and academic partnerships—while working closely with aligned medical groups representing more than 14,000 physicians to develop and support physician educators. Her work centers on building innovative training pathways that address physician workforce needs, align with evolving care delivery models, and strengthen long-term system capability, with the goal of quadrupling Sutter's GME footprint by 2030 to become the largest community-based GME program in California. Learn more about Dr. Mazotti - https://www.linkedin.com/in/lindsay-mazotti Partner with Bright Spots Ventures: If you are interested in speaking with the Bright Spots Ventures team to brainstorm how we can help you grow your business via content and relationships, email hkrish@brightspotsventures.com. About Bright Spots Ventures: Bright Spots Ventures is a healthcare strategy and engagement company that creates content, communities, and connections to accelerate innovation. We help healthcare leaders discover what's working, and how to scale it. By bringing together health plan, hospital, and solution leaders, we facilitate the exchange of ideas that lead to measurable impact. Through our podcast, executive councils, private events, and go-to-market strategy work, we surface and amplify the "bright spots" in healthcare—proven innovations others can learn from and replicate. At our core, we exist to create trusted relationships that make real progress possible. Visit our website at www.brightspotsinhealthcare.com. Visit our website:  www.brightspotsinhealthcare.com. Follow Bright Spots in Healthcare: https://www.linkedin.com/company/shared-purpose-connect

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves away from "blind" invasive biopsies toward precision imaging like MRI and PSMA PET scans.Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.WHAT YOU'LL LEARN IN THIS EPISODE:✅ Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.✅ The difference between "visible" tumors on imaging vs. microscopic disease.✅ How PSA density acts as the crucial "tie-breaker" for indeterminate results.✅ The future of "See and Treat": Targeting lesions while avoiding surgery side effects.✅ Why tumor location (Anterior vs. Posterior) changes your treatment options.✅ How AI and new magnets are making MRI screening cheaper and faster.

With Piotr Futyma, St. Joseph's Heart Rhythm Center, Rzeszow - Poland, Stefan Simovic, Faculty of Medical Sciences, University of Kragujevac, Kragujevac - Serbia and Anthony Li, St George's University of London, London - UK. In this episode of EHRA Cardio Talk, we welcome Piotr Futyma, a leading expert in bipolar ablation and an active member of the EHRA Scientific Initiatives Committee. Together with hosts Stefan Simovic and Anthony Li, he explores the evolving role of bipolar ablation, discusses current challenges and future opportunities, and shares practical insights from clinical experience.

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves away from "blind" invasive biopsies toward precision imaging like MRI and PSMA PET scans.Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.WHAT YOU'LL LEARN IN THIS EPISODE:✅ Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.✅ The difference between "visible" tumors on imaging vs. microscopic disease.✅ How PSA density acts as the crucial "tie-breaker" for indeterminate results.✅ The future of "See and Treat": Targeting lesions while avoiding surgery side effects.✅ Why tumor location (Anterior vs. Posterior) changes your treatment options.✅ How AI and new magnets are making MRI screening cheaper and faster.

Grieving is a uniquely human emotion – or is it? Is the apparent attachment of elephants or orcas to the bodies of dead relatives a sign of grief, or simply an instinctive behaviour without emotional implications? Why do some people seem able to handle grief so much better than others? And how close are we to finding a pharmaceutical ‘cure' for grief…and if we find it, should we use it?This lecture was recorded by Professor Robin May on the 21st of January 2026 at Barnard's Inn Hall, LondonProfessor of Infectious Disease at the University of Birmingham, and (interim) Chief Scientist at the UK Health Security Agency, Robin May was appointed Gresham Professor of Physic in May 2022. Between July 2020 and September 2025 he served as Chief Scientific Adviser at the Food Standards Agency (FSA).Professor May's early training was in Plant Sciences at the University of Oxford, followed by a PhD on mammalian cell biology at University College London and the University of Birmingham. After postdoctoral research on gene silencing at the Hubrecht Laboratory, The Netherlands, he returned to the UK in 2005 to establish a research program on human infectious diseases. He was Director of the Institute of Microbiology and Infection at the University of Birmingham from 2017-2020. Professor May continues his work on Infectious Disease at the University of Birmingham. A Fellow of the Academy of Medical Sciences, Wolfson Royal Society Research Merit Fellow and Fellow of the American Academy of Microbiology, Professor May specialises in research into human infectious diseases, with a particular focus on how pathogens survive and replicate within host organisms.As the FSA's Chief Scientific Adviser, Professor May provides expert scientific advice to the UK government and plays a critical role in helping to understand how scientific developments will shape the work of the FSA, as well as the strategic implications of any possible changes.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/why-grieveGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Send us a textIn episode #170 we spoke with researcher Dr. David Church about:The crucial role of muscle protein synthesis in endurance athletesThe role of essential amino acids on muscle growth and recoveryThe impact of sleep deprivation on muscle recovery and performance.Dr. David Church, the Director of the Center for Translational Research in Aging & Longevity at University of Arkansas for Medical Sciences, College of Medicine. Dr. Church obtained his bachelor's degree in exercise science and biochemistry from DePauw University where he played football and baseball. He was an athletic performance intern at Baylor University where he studied exercise and nutritional biochemistry. He obtained his PhD from the University of Central Florida with a focus on enhancing human performance through exercise and nutrition and completed his post-doctoral fellowship in stable-isotope tracer methodology under the mentorship of Drs. Robert R. Wolfe and Arny Ferrando. He has led multiple trials investigating energy restriction in healthy and clinical populations including two active trials on individuals prescribed GLP-1RA's. He has been recognized for his work with the Nutrition Research Achievement Award from the National Strength and Conditioning Society, the Vernon Young International Award for Amino Acid Research from the American Society for Nutrition, and a Fellow of the International Society of Sports Nutrition.Please note that this podcast is created strictly for educational purposes and should never be used for medical diagnosis or treatment.Follow Dr. Church:InstagramWebMentioned:Dr. Dan MooreDr. Mikkel OxfeldtSleep studies:pmc.ncbi.nlm.nih.gov/articles/PMC7785053/pmc.ncbi.nlm.nih.gov/articles/PMC6917985/Dr. Shiloah KviatkovskyDr. Keith Barr, NR episode 82, collagenWhey Protein IsolateEssential Amino AcidsDr. Heather LeidyMORE NR Save 10% on our website with code NEWPOD10 Apply to work with us, click here: https://nutritional-revolution.com/ Follow us @nutritionalrevolution Save 20% on supplements at our trusted online source: https://us.fullscript.com/welcome/kchannell Join Nutritional Revolution's The Feed Club to get $20 off with an additional $20 Feed credit drop every 90 days.: https://thefeed.com/teams/nutritional-revolution If you're interested in sponsoring Nutritional Revolution Podcast, shoot us an email at nutritionalrev@gmail.com.

Share your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9Check out BeerBiceps SkillHouse's YouTube 1O1 Course - https://youtube.beerbicepsskillhouse.in/youtube-101For all BeerBiceps vlog content Watch Life Of BeerBiceps - https://www.youtube.com/@LifeOfBeerBicepsBeerBiceps SkillHouse को Social Media पर Follow करे :-YouTube : https://www.youtube.com/channel/UC2-Y36TqZ5MH6N1cWpmsBRQ Instagram : https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comLevel Supermind - Mind Performance App को Download करिए यहाँ से

Share your guest suggestions hereMail - connect@beerbiceps.comLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9Check out BeerBiceps SkillHouse's YouTube 1O1 Course - https://youtube.beerbicepsskillhouse.in/youtube-101BeerBiceps SkillHouse को Social Media पर Follow करे :-YouTube : https://www.youtube.com/channel/UC2-Y36TqZ5MH6N1cWpmsBRQ Instagram : https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comLevel Supermind - Mind Performance App को Download करिए यहाँ से

“Welcome, welcome our wonderful audience!” Dr. Peter Breggin opened The Breggin Hour this week, talking about the effects of his stroke and about our efforts to seek rehabilitation, offering the best chance of optimizing recovery from brain damage. The indomitable Karen Kingston, who has been exposing the dangers of the mRNA vaccines for over five years, joined us. Peter spent a portion of the hour further detailing his experience of receiving treatment at the AVIV clinic, which offers a very specialized program of Hyperbaric Oxygen Treatment (HBOT). Peter made a comment at some point in the program, stating we must “muster great courage equal to our fear…” That phrase sums up for me my husband's attitude since his stroke. He is forging ahead, determined to embrace with both arms the work required to heal. During the third segment, we lost audio with Karen Kingston, so Peter and I finished up discussing artificial intelligence, and Karen's point that AI has been introduced just at a time when the human population is suffering from unprecedented amounts of neurological damage, from the mRNA vaccines as well as from other sources. She pointed out that the creators of the AI programs being used were doing the thinking—the cognitive work—for the individuals using it, which means humans are doing less independent thinking and creating increasing dependency upon outside sources. The neuropsychiatric damage done by mRNA vaccines is being clearly identified. Peter was a coauthor, along with other noted experts, of a recently published scientific paper: “Association Between COVID-19 Vaccination and Neuropsychiatric Conditions,” published in the International Journal of Innovative Research in Medical Science. The paper details over 58 profound neurological adverse effects resulting from mRNA vaccines. Dr. James Thorp spearheaded this research as lead author. The show was a mix of the deeply personal and an examination of some of the threats to humanity's future, with some sweet moments between Peter and Ginger.

“At some point, feeling good wins over old thoughts.” –VJ HamiltonStruggling with autoimmune disease — or uncomfortable symptoms that you've just learned to live with? What if you could reverse your symptoms? I'm so excited to talk with VJ Hamilton, registered nutritionist and a functional medicine practitioner who specializes in autoimmune disease.I was diagnosed with celiac disease fairly late in life. When I was diagnosed, it just made so much sense and explained so many things. It also led to change. And that can be hard to navigate on your own.Perimenopause and menopause symptoms and those of autoimmune diseases — like brain fog, joint aches, and fatigue — can be signs of both. Plus shifts in hormones can certainly trigger changes or unmask hidden inflammation. Testing and treatment can help.We talk about: Autoimmune disease 101 — what we're actually talking aboutTriggers vs. root causes and how to find the root causeHow to advocate for yourself with doctors and what other practitioner you might want to seeSimple changes you can make to improve your healthFocus not on what you have to cut out for food or what exercise you have to do, but what you need and what you likeEating whole foods instead of prepared meals and how to navigate restaurants and special eventsABOUT VJVJ Hamilton is the founder of The Autoimmunity Nutritionist and an expert in autoimmune disease, specialising in skin disorders, chronic fatigue, joint health, and digestive issues for both men and women.As a Registered Nutritionist with a Medical Science degree (BSc) in Biochemistry & Immunology and having completed the full certification programme at the renowned Institute for Functional Medicine, VJ uses evidence-based nutritional therapies to support her clients in transforming their health.LINKShttps://theautoimmunitynutritionist.com/https://www.instagram.com/theautoimmunitynutritionist/ https://www.linkedin.com/in/theautoimmunitynutritionist/ DOABLE CHANGESAt the end of every episode, we share three doable changes, so you can take what you've heard and put it into action. Action is where change happens. But here's the thing: when we have a goal, a wish, a desire bubbling up in us, it can feel really huge. Sometimes we stop ourselves in our tracks based on how huge our desire feels. Change needs action, but it doesn't need huge action. When we focus on the next step, the next Doable Change that we can integrate into our lives, we don't get stuck and we create momentum. Choose one Doable Change that resonates with you today and really play with it. Fit it into your life, your days, make it work for you — then move on to your next Doable Change. Here are Three Doable Changes from this conversation: MAKE A LIST OF THINGS YOU LOVE TO DO. Changing your lifestyle doesn't have to be terrible! Make a list of things you love to do. Ways you like to be active, rest, connect with others. Make a list of things that make you feel good! Plan for more of those things in your life. That might look like swapping dancing for a gym session or eating food that gives you energy or going to bed on time.RESET IDEAS AROUND FOOD. Here are a few ways to try this Doable Change. First, instead of asking, “What do I have to cut out?” think about what foods you can...

Dr. Uri Tabori is a Staff Physician in the Division of Haematology/Oncology, Senior Scientist in the Genetics & Genome Biology program, and Principal Investigator of The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children (SickKids). Uri is also a Professor in Paediatrics and Associate Professor in the Institute of Medical Sciences at the University of Toronto. Uri works as a physician treating kids with cancer, particularly brain tumors. Through his research, he is working to identify drugs and make new discoveries that may cure cancers or improve patients' lives. When he's not hard at work in the lab or clinic, Uri enjoys spending time with his family, watching American football, and exploring the wilderness of Canada. He is especially fond of canoeing and canoe camping with his family. He received his MD from the Hadassah School of Medicine of Hebrew University in Israel. Afterwards, he completed a Rotating Internship and his Residency in Pediatrics at the Sorasky Medical Center in Israel. Next, Uri accepted a Fellowship in Pediatric Hematology and Oncology at the Sheba Medical Center in Israel. He served as a Staff Physician in Pediatric Hematology and Oncology at The Sheba Medical Center for about a year before accepting a Research and Clinical Fellowship at The Hospital for Sick Children in Canada SickKids where he remains today. Over the course of his career, Uri has received numerous awards and honors, including the Early Researcher Award from the Ontario Ministry of Development and Innovation, the New Investigator Award from the Canadian Institute of Health Research, the Junior Physician Research Award from the University of Toronto Department of Pediatrics, The New Investigator Award from the Terry Fox Foundation, A Eureka! new investigator award from the International Course of Translational Medicine, A Merit Award from the American Society of Clinical Oncology Annual Meeting, and The Young Investigator Award from the Canadian Neuro-Oncology Society. In our interview, Uri shares more about his life, science, and clinical care.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover Jimmy Kimmel's controversial return to television, a Supreme Court ruling that could reshape presidential power, the growing struggles of America's farmers and truckers, and new White House warnings about Tylenol and autism. From free speech fights to medical debates, today's brief connects culture, politics, and science shaping America's future.   Jimmy Kimmel Returns to Air with FCC Debate: Disney announced Kimmel would return, calling his remarks “ill-timed and insensitive” but not admitting his claims about Charlie Kirk's assassin were lies. Sinclair caved after death threats, canceling a Kirk tribute and airing Kimmel again. Senators Rand Paul and Ted Cruz blasted Trump's FCC for even raising news distortion, with Cruz comparing it to “Goodfellas.” Bryan warned, “We cannot sit down with the modern Democrat party… they assassinate people who get in the way — like Charlie Kirk.”   Supreme Court Expands Presidential Power: In a 6–3 decision, the Court allowed Trump to fire a Democrat FTC commissioner while hearing the full case in December. The ruling challenges the 1935 precedent limiting executive power. Bryan explains it could restore Jefferson-style authority, including presidential impoundment of spending. “Welcome to the new version of American democracy… it's a bit of a mess right now.”   Farmers, Ranchers, and Truckers Under Pressure: New screwworm cases in northern Mexico threaten U.S. cattle herds already at historic lows. Soybean farmers face collapse as Xi stops buying American crops, while truckers lose money under depressed rates and costly California regulations. Bryan calls for revoking visas of foreign drivers who “can't read or speak English and are killing people on the road.”   White House Links Tylenol to Autism: Trump's HHS and FDA advised pregnant women to limit acetaminophen after new studies showed it can cross the placenta, cause oxidative stress, and disrupt brain development. Critics called the claims weak, but Bryan compared it to past medical dogmas debunked by Dr. Barry Marshall, who proved ulcers were caused by bacteria: “Quite literally the entire world of Medical Science was wrong. That one doctor was right.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Jimmy Kimmel FCC news distortion, Rand Paul Ted Cruz Goodfellas FCC quote, Sinclair cancels Charlie Kirk tribute, Supreme Court Trump FTC ruling, presidential impoundment Jefferson precedent, U.S. screwworm outbreak Nuevo Leon, U.S. soybean farmers China ban, trucker wages California EV mandate, Trump revoke foreign trucker visas, Trump HHS FDA Tylenol autism warning, acetaminophen oxidative stress fetus, Dr. Barry Marshall ulcer Nobel Prize